Φορτώνει......
HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer
Tamoxifen is a commonly used drug to treat estrogen receptor-positive patients with breast cancer. Despite the outstanding efficacy of tamoxifen, approximately one-third of patients develop resistance toward it, thereby presenting a therapeutic challenge. HOX genes may be involved in the acquisition...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Cancer |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Ivyspring International Publisher
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8210559/ https://ncbi.nlm.nih.gov/pubmed/34149926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.59740 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|